1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1645
  6. Examiner Dickens

Examiner Dickens Amelia N

1645-DICKENS-AMELIA-N

Employment Information

Art Unit:1645 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
585 — Chemistry of hydrocarbon compounds
536 — Organic compounds -- part of the class 532-570 series
Phone:(571) 272-0381
Email:amelia.dickens@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biolgy)
Service:4 years
Grade:GS-12

Grant Rate and Difficulty Ranking

87
3-Year Grant rate: 37% over 59 cases
Difficulty: Very Hard
Difficulty Percentile: 87th

With Examiner Dickens, you have a 37% chance of getting an issued patent by 3 years after the first office action. Examiner Dickens is a very hard examiner and in the 87th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Dickens, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1645

Examiner Dickens's grant rate is lower than that of Art Unit 1645 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Dickens 2.1
Art Unit 1645 1.7

Interview Benefit

Grant Rate without Interview

Examiner Dickens has granted 19 of 46 cases without any applicant-requested interviews for a grant rate of 41%.

Grant Rate with Interview

Examiner Dickens has granted 3 of 13 cases with at least one applicant-requested interview for a grant rate of 23%.

Interview Benefit

With Examiner Dickens, conducting an interview decreases your chance of getting a patent granted by 44%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17432671 Fermentation Process Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18029360 Bacillus Coagulans Having Blood Glucose Reduction Efficacy, And Application Thereof Patented View
17416725 Systems And Methods For Microcolony Growth And Microbial Cell Characterization Abandoned View
17774385 Mycobacterial Compositions And Biomarkers For Use In Treatment And Monitoring Of Therapeutic Responsiveness Abandoned View
17624046 Plasmodium Antibodies Abandoned View
17856241 Synthetic Biomarkers For Differential Serological Diagnosis Of Cutaneous Leishmaniasis (Cl) Caused By Various Leishmania Species Abandoned View
16620155 Chimeric Receptor For Use In Whole-Cell Sensors For Detecting Analytes Of Interest Patented View
17617706 Novel Secreted Antigens For Diagnosis Of Active Babesia Microti And Babesia Duncani Infection In Humans And Animals Abandoned View
17493932 Delivery Vehicle Abandoned View
16341248 Novel Therapy Abandoned View
16957505 Innate Targeting Of Adoptive Cellular Therapies Patented View
16050312 Method For Precise Identification, Targeting And Delivery Of Directed Therapies With The Use Of Bacteria For The Destruction Of Cancerous Cells Abandoned View
18212857 Microparticles From Streptococcus Pneumoniae As Vaccine Antigens Abandoned View
17999246 Cysteine Protease Patented View
17372291 Bacterial-Derived Nitrogen Source For Ethanol Fermentation Patented View
17232236 Method For Analyzing Microorganism Abandoned View
17623072 Botulinum Toxin Type A Complex, And Formulation Thereof And Usage Method Therefor Patented View
17647571 Antigenic Composition(S) And Method(S) Of Use Against Porphyromonas Gingivalis For The Prevention And/or Treatment Of Infection And/or Diseases Abandoned View
17766738 Method For Preparing Immobilized Arginine Deiminase (Adi) And Producing [14/15n]-L-Citrulline Patented View
17252863 Probiotic Compositions And Uses Thereof Abandoned View
17685994 Peptides With Phytosanitary Activities Abandoned View
17055294 Streptococcal Toxic Shock Syndrome Abandoned View
18530981 Treatment Of Uterine Fibroids Using Purified Collagenase Abandoned View
17327081 Ace2 Fusion Proteins And Uses Thereof Abandoned View
17483920 Proteins With Diagnostic And Therapeutic Uses Abandoned View
17048155 Tick Vaccine Abandoned View
17795329 Bacterial Admixtures Abandoned View
18186793 Novel Anti-Pd-1 Antibodies Abandoned View
17433067 Production Of High Purity Organic Lactic Acid And Its Salts And Various Applications Thereof Patented View
17257422 Aqueous Topical Compositions Comprising Viable Probiotic Bacteria Abandoned View
16302938 Compositions And Methods For The Expression Of Eukaryotic Oligosaccharides On Bacterial Outer Membrane Vesicles Abandoned View
18330411 Protein For Rapid, Efficient Capture Of Antigens Patented View
17348994 Designer Peptide Opsonins Abandoned View
15734107 Composition For Treating Or Preventing Colorectal Disease Containing Construct For Expression Of P8 Protein Derived From Lactic Acid Bacteria Patented View
17187771 Methods Of Reducing Polysorbate Degradation In Drug Formulations Abandoned View
17400790 Use Of Variovorax Microbes As An Alternative Treatment For Coccidiosis Abandoned View
17260693 Thermostable Phycobiliproteins Produced From Recombinant Arthrospira Patented View
17816045 Synergistic Combination Of Alum And Non-Liposome, Non-Micelle Particle Vaccine Adjuvants Abandoned View
17915527 Application Of Geraniol In Preparation Of Formulation For Promoting Synthesis Of Pseudomonas Aeruginosa 3oc12-Hsl Signal Molecules Abandoned View
18198519 Treatment Delivery System And Method Abandoned View
18315255 Modified Bacteriophage Abandoned View
18309590 High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal Antibody Patented View
17598652 Garlic Extract And Method Thereof Patented View
18659215 Ph20 Polypeptide Variants, Formulations And Uses Thereof Patented View
16979117 Recombinant Alkaline Phosphatase For Use In Treating Sepsis-Associated Acute Kidney Injury Patented View
17650487 Attenuated Bordetella Strains Abandoned View
17385958 Method For Identifying And Treating Streptococcus Pyogenes Infection Abandoned View
17251410 Therapeutic Methods Using Bacterial Strains Which Are Capable Of Increasing Adenosine Levels Abandoned View
17415976 Pharmabiotic Treatments For Metabolic Disorders Abandoned View
17422654 Ethanol Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.